RAPID ELECTRONIC DETECTION OF CELL SURFACE PROTEINS

细胞表面蛋白质的快速电子检测

• 批准号: 6062363
• 负责人: CYNTHIA C. BAMDAD
• 金额: $ 13万
• 依托单位: MINERVA BIOTECHNOLOGIES CORPORATION
• 依托单位国家: 美国
• 财政年份: 2000
• 资助国家: 美国
• 起止时间: 2000-01-01 至 2000-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6062363
• 关键词: biomarker; biomedical equipment development; histopathology; human tissue; microelectrodes; monitoring device; nucleic acid quantitation /detection; protein structure function; semiconduction; single cell analysis; surface antigens; technology /technique development

Minerva Biotechnologies will develop MEMS (microelectronic micromechanical systems) technology to electronically detect and quantitate proteins on the surface of an intact cell and screen for drugs to block them. Preliminary results indicate that the technology can be used to quantitate proteins on the surface of a single cell (100 molecule detection): a level not possible with existing technology. Our approach would allow more accurate assessment of how protein expression is altered, on the surface of cancer cells, and eliminate uncertainties introduced by large heterogeneous cell populations. We will extend the system so that proteins on the surface of cells embedded in a tumor section can be electronically analyzed, in situ. Each sector (dimensions similar to a cell) of the, tissue specimen could be analyzed for protein content and expression level, then correlated with histopathology. This capability will ensure the relevance of single cell analysis because it will enable the researcher to identify protein patterns that are associated with cancer cells and discard random aberrant protein expression. Capability to quantitate tumor markers will help clinicians assess prognosis and predict response to therapy. The electronics of the technology are inexpensive and miniaturizable, making it compatible with either basic research or clinical settings. PROPOSED COMMERCIAL APPLICATIONS: The technology we are seeking SBIR funding to develop will allow for the cheap, rapid and ultra-sensitive detection of proteins on the surface of intact cells. The technology is immediately applicable to cancer diagnosis and the monitoring of response to therapy . The same technology can be massively multiplexed using computer microelectronics for screening of anti-cancer drug candidates on cells and for the identification of likely anti-cancer drug targets by identifying interacting receptors and ligands.

Minerva Biotechnologies将开发MEMS（微电子微机械系统）技术，以电子方式检测和定量完整细胞表面上的蛋白质，并筛选出药物以阻止它们。初步结果表明，该技术可用于定量单个细胞表面上的蛋白质（100分子检测）：现有技术不可能的水平。我们的方法将可以更准确地评估蛋白质表达在癌细胞表面上的改变，并消除大型异质细胞种群引入的不确定性。我们将扩展系统，以便可以以电子方式分析嵌入肿瘤部分中嵌入肿瘤部分的细胞表面的蛋白质。 可以分析组织标本的每个扇形（类似于细胞的尺寸）的蛋白质含量和表达水平，然后与组织病理学相关。该能力将确保单细胞分析的相关性，因为它将使研究人员能够鉴定与癌细胞相关的蛋白质模式并丢弃随机异常蛋白表达。 定量肿瘤标志物的能力将有助于临床医生评估预后并预测对治疗的反应。该技术的电子设备廉价且微型化，使其与基础研究或临床环境兼容。拟议的商业应用：我们正在寻求SBIR资金开发的技术将允许对完整细胞表面上蛋白质的廉价，快速和超敏感性检测。该技术立即适用于癌症诊断和对治疗反应的监测。可以使用计算机微电子学通过鉴定相互作用的受体和配体来鉴定相同的技术，以使用计算机微电子学筛查细胞上的抗癌药物候选物，并鉴定可能的抗癌药物靶标。